321 related articles for article (PubMed ID: 27916480)
1. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
McElvaney NG; Burdon J; Holmes M; Glanville A; Wark PA; Thompson PJ; Hernandez P; Chlumsky J; Teschler H; Ficker JH; Seersholm N; Altraja A; Mäkitaro R; Chorostowska-Wynimko J; Sanak M; Stoicescu PI; Piitulainen E; Vit O; Wencker M; Tortorici MA; Fries M; Edelman JM; Chapman KR;
Lancet Respir Med; 2017 Jan; 5(1):51-60. PubMed ID: 27916480
[TBL] [Abstract][Full Text] [Related]
2. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
3. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
4. Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency.
Tortorici MA; Rogers JA; Vit O; Bexon M; Sandhaus RA; Burdon J; Chorostowska-Wynimko J; Thompson P; Stocks J; McElvaney NG; Chapman KR; Edelman JM
Br J Clin Pharmacol; 2017 Nov; 83(11):2386-2397. PubMed ID: 28662542
[TBL] [Abstract][Full Text] [Related]
5. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency.
Parr DG; Dirksen A; Piitulainen E; Deng C; Wencker M; Stockley RA
Respir Res; 2009 Aug; 10(1):75. PubMed ID: 19678952
[TBL] [Abstract][Full Text] [Related]
6. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
Chapman KR; Chorostowska-Wynimko J; Koczulla AR; Ferrarotti I; McElvaney NG
Int J Chron Obstruct Pulmon Dis; 2018; 13():419-432. PubMed ID: 29430176
[TBL] [Abstract][Full Text] [Related]
7. Biochemical efficacy and safety of a new, ready-to-use, liquid alpha-1-proteinase inhibitor, GLASSIA (alpha1-proteinase inhibitor (human), intravenous).
Sandhaus RA; Stocks J; Rouhani FN; Brantly M; Strauss P
COPD; 2014 Feb; 11(1):17-25. PubMed ID: 23822603
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
9. [Expert statement for augmentation therapy in patients with alpha-1 antitrypsin deficiency].
Köhnlein T; Schmidt-Scherzer K; Greulich T; Bals R
Pneumologie; 2014 Jul; 68(7):492-5. PubMed ID: 25006842
[TBL] [Abstract][Full Text] [Related]
10. Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency.
Chorostowska-Wynimko J
COPD; 2016 Dec; 13(6):807-815. PubMed ID: 27172295
[TBL] [Abstract][Full Text] [Related]
11. Progress of emphysema in severe alpha 1-antitrypsin deficiency as assessed by annual CT.
Dirksen A; Friis M; Olesen KP; Skovgaard LT; Sørensen K
Acta Radiol; 1997 Sep; 38(5):826-32. PubMed ID: 9332238
[TBL] [Abstract][Full Text] [Related]
12. Safety of biweekly α
Greulich T; Chlumsky J; Wencker M; Vit O; Fries M; Chung T; Shebl A; Vogelmeier C; Chapman KR; McElvaney NG;
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30237305
[TBL] [Abstract][Full Text] [Related]
13. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.
Sclar DA; Evans MA; Robison LM; Skaer TL
Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.
Dirksen A; Dijkman JH; Madsen F; Stoel B; Hutchison DC; Ulrik CS; Skovgaard LT; Kok-Jensen A; Rudolphus A; Seersholm N; Vrooman HA; Reiber JH; Hansen NC; Heckscher T; Viskum K; Stolk J
Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1468-72. PubMed ID: 10556107
[TBL] [Abstract][Full Text] [Related]
15. α1-Antitrypsin Deficiency.
Hatipoğlu U; Stoller JK
Clin Chest Med; 2016 Sep; 37(3):487-504. PubMed ID: 27514595
[TBL] [Abstract][Full Text] [Related]
16. Comparative biochemical efficacy analysis of an alpha
Li Z; Franke RM; Morris D; Yel L
Pulm Pharmacol Ther; 2022 Jun; 73-74():102124. PubMed ID: 35314325
[TBL] [Abstract][Full Text] [Related]
17. Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency--three-year follow-up.
Schwaiblmair M; Vogelmeier C; Fruhmann G
Respiration; 1997; 64(1):10-5. PubMed ID: 9044469
[TBL] [Abstract][Full Text] [Related]
18. Pathogen safety and characterisation of a highly purified human alpha
Kee S; Weber D; Popp B; Nowak T; Schäfer W; Gröner A; Roth NJ
Biologicals; 2017 May; 47():25-32. PubMed ID: 28377078
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough.
Balbi B; Ferrarotti I; Miravitlles M
Eur Respir J; 2016 Jan; 47(1):35-8. PubMed ID: 26721962
[No Abstract] [Full Text] [Related]
20. The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials.
Ma S; Lin YY; Cantor JO; Chapman KR; Sandhaus RA; Fries M; Edelman JM; McElvaney G; Turino GM
Chronic Obstr Pulm Dis; 2016 Nov; 4(1):34-44. PubMed ID: 28848909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]